Investment Thesis
Immuneering is a pre-revenue pharmaceutical company with zero sales and significant operating losses (-$15.3M), though improving trends show operating efficiency gains. While the balance sheet is fortress-like with $47.3M cash and minimal debt, negative free cash flow of -$18.5M means the company is burning through reserves, creating execution risk dependent entirely on successful drug commercialization.
Strengths
- Exceptional financial fortress: $206.5M equity with only $8.3M liabilities and zero long-term debt
- Strong cash position of $47.3M provides runway for continued R&D operations
- Improving loss trajectory: net loss decreased 8.2% YoY and diluted EPS improved 37.7%, indicating operational progress
- Outstanding liquidity (32.45x current ratio) eliminates near-term solvency concerns
Risks
- Zero revenue with no commercialized products generates existential business model risk
- Negative free cash flow of -$18.5M annually will deplete cash reserves within ~2.5 years without revenue or financing
- Pharmaceutical development carries high clinical failure rates; entire value depends on unproven pipeline success
- No revenue means zero profitability and no path to sustainability without product commercialization
- Only 1 insider filing in 90 days suggests minimal insider conviction or activity
Key Metrics to Watch
- Monthly cash burn rate trend and total cash runway duration
- Clinical trial advancement and regulatory milestones for lead drug candidates
- Timeline to first product revenue generation and market launch
- Operating cash flow trajectory toward breakeven
- Partnerships, licensing agreements, or strategic financing activities
Financial Metrics
Revenue
0.0
Net Income
-13.5M
EPS (Diluted)
$-0.21
Free Cash Flow
-18.5M
Total Assets
214.8M
Cash
47.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-6.5%
ROA
-6.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
32.45x
Quick Ratio
32.45x
Debt/Equity
0.00x
Debt/Assets
3.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T06:43:44.657824 |
Data as of: 2026-03-31 |
Powered by Claude AI